JP2014525429A - Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物 - Google Patents

Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物 Download PDF

Info

Publication number
JP2014525429A
JP2014525429A JP2014527686A JP2014527686A JP2014525429A JP 2014525429 A JP2014525429 A JP 2014525429A JP 2014527686 A JP2014527686 A JP 2014527686A JP 2014527686 A JP2014527686 A JP 2014527686A JP 2014525429 A JP2014525429 A JP 2014525429A
Authority
JP
Japan
Prior art keywords
seq
antigen
tlr agonist
aureus
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014527686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525429A5 (enExample
Inventor
ファビオ バグノーリ，
バーバラ バウドナー，
シモーネ ブファーリ，
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2014525429A publication Critical patent/JP2014525429A/ja
Publication of JP2014525429A5 publication Critical patent/JP2014525429A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2014527686A 2011-09-01 2012-08-31 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物 Pending JP2014525429A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161530162P 2011-09-01 2011-09-01
US61/530,162 2011-09-01
US201261607999P 2012-03-07 2012-03-07
US61/607,999 2012-03-07
PCT/EP2012/067032 WO2013030378A1 (en) 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens

Publications (2)

Publication Number Publication Date
JP2014525429A true JP2014525429A (ja) 2014-09-29
JP2014525429A5 JP2014525429A5 (enExample) 2015-10-01

Family

ID=46763095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014527686A Pending JP2014525429A (ja) 2011-09-01 2012-08-31 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物

Country Status (14)

Country Link
US (1) US20140363461A1 (enExample)
EP (1) EP2763695A1 (enExample)
JP (1) JP2014525429A (enExample)
KR (1) KR20140066212A (enExample)
CN (1) CN104093418A (enExample)
AU (1) AU2012300765A1 (enExample)
BR (1) BR112014004782A2 (enExample)
CA (1) CA2847204A1 (enExample)
IL (1) IL231104A0 (enExample)
IN (1) IN2014CN02152A (enExample)
MX (1) MX2014002363A (enExample)
RU (1) RU2014112343A (enExample)
SG (1) SG11201400210RA (enExample)
WO (1) WO2013030378A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523732T5 (es) * 2009-04-03 2023-10-23 Momenta Pharmaceuticals Inc Control de composiciones de copolímeros
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
AU2012214677B2 (en) 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
KR20140066212A (ko) * 2011-09-01 2014-05-30 노파르티스 아게 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물
HRP20161354T1 (hr) * 2012-03-07 2016-12-02 Glaxosmithkline Biologicals Sa Argininske soli agonista tlr7
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
CN104619336A (zh) * 2012-08-31 2015-05-13 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
US20150191513A1 (en) * 2012-08-31 2015-07-09 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
EP3122378B1 (en) 2014-03-26 2019-12-11 GlaxoSmithKline Biologicals S.A. Mutant staphylococcal antigens
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119343A2 (en) * 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2011027222A2 (en) * 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JP2013503884A (ja) * 2009-09-02 2013-02-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｌｒ活性モジュレーターとしての化合物および組成物
JP2013538217A (ja) * 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (de) 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
US20060188515A1 (en) 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
NZ544542A (en) 2003-07-24 2009-01-31 Merck & Co Inc Polypeptides for inducing a protective immune response against staphylococcus aureus
CA2555342A1 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
EP1939201A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
EP1939198A4 (en) 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
AU2007216247A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as TLR7 modulators
AU2007259415B2 (en) 2006-06-12 2013-09-26 Glaxosmithkline Biologicals Sa Use of alpha-toxin for treating and preventing Staphylococcus infections
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
US8338593B2 (en) 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
TW200843779A (en) 2007-02-19 2008-11-16 Smithkline Beecham Corp Compounds
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
JP5400763B2 (ja) 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
ES2359123T3 (es) 2007-08-03 2011-05-18 Pfizer Limited Imidazopiridinonas.
CA2697538C (en) 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
PL2268618T3 (pl) 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
CN103396415B (zh) 2008-03-24 2016-08-10 4Sc股份有限公司 新的取代的咪唑并喹啉化合物
WO2010014913A1 (en) 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
SI2445522T1 (sl) * 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
AU2010272505B2 (en) 2009-07-16 2015-09-17 Glaxosmithkline Biologicals S.A. Treatment of infections
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP5848748B2 (ja) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ 感染症、炎症、呼吸器疾患などの処置に使用するｔｌｒ２アゴニストとしての化合物（システインベースのリポペプチド）および組成物
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
KR20140066212A (ko) * 2011-09-01 2014-05-30 노파르티스 아게 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물
JP2015510872A (ja) * 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
US20150125486A1 (en) * 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
US9375471B2 (en) * 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US20150191513A1 (en) * 2012-08-31 2015-07-09 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
CN104619336A (zh) * 2012-08-31 2015-05-13 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
JP2015528456A (ja) * 2012-08-31 2015-09-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
RU2015106930A (ru) * 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
GB201219420D0 (en) * 2012-10-29 2012-12-12 Novartis Ag Staphyloccal immunogens
TR201807340T4 (tr) * 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
EP3122378B1 (en) * 2014-03-26 2019-12-11 GlaxoSmithKline Biologicals S.A. Mutant staphylococcal antigens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119343A2 (en) * 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2011027222A2 (en) * 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JP2013503884A (ja) * 2009-09-02 2013-02-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｌｒ活性モジュレーターとしての化合物および組成物
JP2013538217A (ja) * 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着

Also Published As

Publication number Publication date
MX2014002363A (es) 2014-04-14
KR20140066212A (ko) 2014-05-30
US20140363461A1 (en) 2014-12-11
AU2012300765A1 (en) 2014-03-13
BR112014004782A2 (pt) 2017-03-21
CA2847204A1 (en) 2013-03-07
CN104093418A (zh) 2014-10-08
EP2763695A1 (en) 2014-08-13
SG11201400210RA (en) 2014-03-28
IL231104A0 (en) 2014-04-30
RU2014112343A (ru) 2015-10-10
WO2013030378A1 (en) 2013-03-07
IN2014CN02152A (enExample) 2015-09-04

Similar Documents

Publication Publication Date Title
JP2014525429A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物
JP7295895B2 (ja) 追加免疫ワクチンのアジュバント化された処方物
CA3066792C (en) Neisseria meningitidis compositions and methods thereof
JP2010500399A (ja) 尿路病原性大腸菌由来の免疫原
JP2008529558A (ja) 髄膜炎／敗血症に関連する大腸菌由来のタンパク質および核酸
US20150258190A1 (en) Nicotinamide as adjuvant
JP2015529212A (ja) 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
KR102027429B1 (ko) 돌연변이 스태필로코쿠스 항원
JP2015509520A (ja) 狂犬病ウイルス免疫原のアジュバント化製剤
CN100384476C (zh) 含有作为疫苗辅药的磷酸铁的疫苗组合物
KR20240147612A (ko) 향상된 효능을 갖는 알루미늄계 애주번트를 제조하는 방법
NZ747917B2 (en) Neisseria meningitidis compositions and methods thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170206